Clinical Trial Update: Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

View source ↗

Summary

This clinical trial update examines uptake of two imaging radiotracers, 18F-dopa and 123I-MIBG, in patients with neuroblastoma to evaluate imaging performance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 18F-DOPA (fluorodopa)
• [123I]-MIBG (Iodine-123 labeled MIBG (123I-MIBG))

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Neuroblastoma | Status: UNKNOWN